Art. -Nr.: HY-121235

Clonixin

(Synonyms: SCH-10304)

Kundenbewertung

Based on 1 Customer Validation

Clonixin (SCH-10304) is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.88%
CAS. Nr.: 17737-65-4
Formel: C₁₃H₁₁ClN₂O₂
Molecular Weight:262.69

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Clonixin Chemical Structure

CAS. Nr.: 17737-65-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle COX Isoform-spezifische Produkte anzeigen :

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Bone marrow cell	EC₅₀	>20 μM Compound: Clonixin	Induction of bone marrow cell differentiation isolated from ER-HOXA9 fusion protein expressed mouse harboring GFP-lysozyme assessed as upregulation of CD11b/MAC1 after 4 days by flow cytometry Induction of bone marrow cell differentiation isolated from ER-HOXA9 fusion protein expressed mouse harboring GFP-lysozyme assessed as upregulation of CD11b/MAC1 after 4 days by flow cytometry	[PMID: 27994748]
THP-1	EC₅₀	>20 μM Compound: Clonixin	Induction of human THP1 cell differentiation after 4 days by flow cytometry Induction of human THP1 cell differentiation after 4 days by flow cytometry	[PMID: 27994748]
U-937	EC₅₀	>20 μM Compound: Clonixin	Induction of human U937 cell differentiation after 4 days by flow cytometry Induction of human U937 cell differentiation after 4 days by flow cytometry	[PMID: 27994748]

In Vivo

Clonixin (142 mg/kg; p.o.; daily; 7 days) administered during either the inflammatory or fibrotic phase of Bleomycin (HY-108345)-induced pulmonary fibrosis in male Sprague Dawley rats significantly reduces lung fibrosis, oxidative stress, inflammation, and improves respiratory function, with marked reductions in hydroxyproline content and Ashcroft scores^[1].
Clonixin (40-120 mg/kg; i.p.; single dose) produces dose-dependent analgesia in the rat formalin nociception model^[3].
Clonixin (i.p.) has an intraperitoneal LD₅₀ of 308.0 mg/kg in Wistar rats^[3].
Clonixin (i.p.) has an intraperitoneal LD₅₀ of 266.4 mg/kg in Swiss AsW mice^[3].
Clonixin (Low-intermediate-high exposure doses; i.v.; single dose) produces dose-dependent hypotension and bradycardia in rats, with reversibility limited to low doses^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley (male, 4-6 weeks old, 200-250 g, bleomycin-induced pulmonary fibrosis)^[1]
Dosage:

142 mg/kg
Administration:

p.o.; daily; 7 days (days 1-7 post-bleomycin or days 8-14 post-bleomycin)
Result:

Attenuated bleomycin-induced body weight loss.
Significantly reduced lung coefficient.
Significantly reduced airway resistance.
Markedly reduced total leukocyte count in bronchoalveolar lavage fluid (BALF).
Significantly reduced lymphocyte count in BALF.
Significantly reduced monocyte count in BALF.
Reduced lung tissue malondialdehyde (MDA) levels, and restored reduced glutathione (GSH), superoxide dismutase (SOD), and catalase levels.
Significantly reduced lung hydroxyproline content.
Significantly reduced Ashcroft fibrosis score.
Reduced immunohistochemical expression of fibrotic markers α-SMA, FAP, and TNF-α in lung tissue, particularly in the days 8-14 dosing group.

Animal Model:

Wistar (adult male and female; formalin-induced nociception model)^[3]
Dosage:

40 mg/kg; 80 mg/kg; 120 mg/kg
Administration:

i.p.; single dose
Result:

Had no effect on formalin-induced nociceptive response at 40 mg/kg.
Produced significant, dose-dependent reductions in pain intensity ratings at 80 mg/kg and 120 mg/kg.
Showed non-linear temporal course of analgesia at 120 mg/kg, with pain ratings returning to control levels by end of 30-minute observation period.
Significantly reduced formalin-induced pain intensity when combined with nifedipine 5 mg/kg at 80 mg/kg.
Was approximately 10 times less potent than nifedipine and morphine in this assay.

Chemical Information

CAS. Nr. 17737-65-4
Appearance Solid
Molecular Weight 262.69
Formel C₁₃H₁₁ClN₂O₂
Color White to off-white
SMILES

O=C(C1=CC=CN=C1NC2=CC=CC(Cl)=C2C)O
Synonyms

SCH-10304
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (380.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8068 mL

19.0338 mL

38.0677 mL

5 mM

0.7614 mL

3.8068 mL

7.6135 mL

10 mM

0.3807 mL

1.9034 mL

3.8068 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Gawli C, et al. Repurposing clonixin and flunixin as anti-fibrotic candidates: Computational and preclinical evaluation in bleomycin-induced pulmonary fibrosis in rats. Res Vet Sci. 2025 Dec;197:105923.
[Content Brief]

[2]. Ferreira H, et al. Interaction of clonixin with EPC liposomes used as membrane models. J Pharm Sci. 2005 Jun;94(6):1277-87.
[Content Brief]

[3]. Bustamante D, et al. Analgesic action of clonixin, nifedipine and morphine using the formalin test. Gen Pharmacol. 1989;20(3):319-22.
[Content Brief]

[4]. Morales MA, et al. Vasorelaxant effect of the analgesic clonixin on rat aorta. Gen Pharmacol. 1995 Mar;26(2):425-30.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8068 mL	19.0338 mL	38.0677 mL	95.1692 mL
	5 mM	0.7614 mL	3.8068 mL	7.6135 mL	19.0338 mL
	10 mM	0.3807 mL	1.9034 mL	3.8068 mL	9.5169 mL
	15 mM	0.2538 mL	1.2689 mL	2.5378 mL	6.3446 mL
	20 mM	0.1903 mL	0.9517 mL	1.9034 mL	4.7585 mL
	25 mM	0.1523 mL	0.7614 mL	1.5227 mL	3.8068 mL
	30 mM	0.1269 mL	0.6345 mL	1.2689 mL	3.1723 mL
	40 mM	0.0952 mL	0.4758 mL	0.9517 mL	2.3792 mL
	50 mM	0.0761 mL	0.3807 mL	0.7614 mL	1.9034 mL
	60 mM	0.0634 mL	0.3172 mL	0.6345 mL	1.5862 mL
	80 mM	0.0476 mL	0.2379 mL	0.4758 mL	1.1896 mL
	100 mM	0.0381 mL	0.1903 mL	0.3807 mL	0.9517 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Clonixin

Reprogramming Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mechanoreceptors Compound Library

Anti-Colorectal Cancer Compound Library

Calcium Channel Blocker Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cytokine Inhibitors Library

Ion Channel Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

FDA Kinase Inhibitor Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

TGF-beta/Smad Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Alle COX Isoform-spezifische Produkte anzeigen

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Clonixin Related Classifications

HY-121235 Related Classifications